Discover open access scientific publications

Search, annotate, share and cite publications

Publications by L. Zhang

P1.01-107 the Impact of Anlotinib on Quality of Life in Patients With Advance NSCLC: Post-Hoc Analysis of a Phase III Randomized Control Trial (ALTER0303)

Journal of Thoracic Oncology

English

P3.12-09 Smad4 Mutation Confers Acquired Neuroendocrine Phenotype in Transformation of Lung Adenocarcinoma to Small Cell Lung Cancer

Journal of Thoracic Oncology

English

P3.13-09 ALTER-0303 Study: Tumor Mutation Index (TMI) for Clinical Response to Anlotinib in Advanced NSCLC Patients at 3rd Line

Journal of Thoracic Oncology

English

P1.01-30 Crizotinib in Advanced Non-Adenocarcinoma, NSCLC (NA-NSCLC) Patients With ALK Rearrangement: A Retrospective Study and Literature Review

Journal of Thoracic Oncology

English

P102 the Correlations of Tumor Mutational Burden Among Single-Region Tissue, Multi-Region Tissues and Blood in NSCLC

Journal of Thoracic Oncology

English

P2.01-116 the Potential of Assessing Blood Tumor Mutation Burden (bTMB) Using a Large Panel

Journal of Thoracic Oncology

English

P025 Which Is the Optimal Immunotherapy for Advanced Non-Squamous Non-Small-Cell Lung Cancer in Combination With Chemotherapy?

Journal of Thoracic Oncology

English

P2.03-041 the Concentration of Avitinib in Cerebrospinal Fluid and Its Efficacy and Safety in NSCLC Patients With T790M Mutation

Journal of Thoracic Oncology

English

P2.01-44 Prognostic Value of TP53 Hot Exon Mutation in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology

English

JCSE01.19 ALTER-0303 Study: Tumor Mutation Index (TMI) for Clinical Response to Anlotinib in Advanced NSCLC Patients at 3rd Line

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by L. Zhang

P1.01-107 the Impact of Anlotinib on Quality of Life in Patients With Advance NSCLC: Post-Hoc Analysis of a Phase III Randomized Control Trial (ALTER0303)

P3.12-09 Smad4 Mutation Confers Acquired Neuroendocrine Phenotype in Transformation of Lung Adenocarcinoma to Small Cell Lung Cancer

P3.13-09 ALTER-0303 Study: Tumor Mutation Index (TMI) for Clinical Response to Anlotinib in Advanced NSCLC Patients at 3rd Line

P1.01-30 Crizotinib in Advanced Non-Adenocarcinoma, NSCLC (NA-NSCLC) Patients With ALK Rearrangement: A Retrospective Study and Literature Review

P102 the Correlations of Tumor Mutational Burden Among Single-Region Tissue, Multi-Region Tissues and Blood in NSCLC

P2.01-116 the Potential of Assessing Blood Tumor Mutation Burden (bTMB) Using a Large Panel

P025 Which Is the Optimal Immunotherapy for Advanced Non-Squamous Non-Small-Cell Lung Cancer in Combination With Chemotherapy?

P2.03-041 the Concentration of Avitinib in Cerebrospinal Fluid and Its Efficacy and Safety in NSCLC Patients With T790M Mutation

P2.01-44 Prognostic Value of TP53 Hot Exon Mutation in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

JCSE01.19 ALTER-0303 Study: Tumor Mutation Index (TMI) for Clinical Response to Anlotinib in Advanced NSCLC Patients at 3rd Line